Clinical Trial Update: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating perioperative dostarlimab in untreated T4N0 or Stage III dMMR/MSI-H resectable colon cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Colonic Neoplasms, Neoplasms, Colon | Phase 3 | Status: RECRUITING